The novel agents are effective against P. aeruginosa, primarily used for infections, including ceftazidone-tazobactam [7,8], ceftazidime-avibactam [9,10], cefiderocol [11], the carbapenem-carbapenem-beta-lactamase combination: imipenem-cilastatin-relebactam, and the monobactam with beta-lactamase inhibitor combination: aztreonam-avibactam. Here, LACTB is linked to infection.